A5061689613- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Systemic Lupus Erythematosus Research
- HIV/AIDS drug development and treatment
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Hepatitis Viruses Studies and Epidemiology
- Diabetes and associated disorders
- Diet, Metabolism, and Disease
- Alcohol Consumption and Health Effects
- Diet and metabolism studies
- Monoclonal and Polyclonal Antibodies Research
- HIV Research and Treatment
- Genetic and Kidney Cyst Diseases
- COVID-19 Clinical Research Studies
- Pancreatitis Pathology and Treatment
- Drug Transport and Resistance Mechanisms
- Autoimmune Bullous Skin Diseases
- Pediatric Hepatobiliary Diseases and Treatments
- Immune Cell Function and Interaction
- Viral Infections and Immunology Research
- Gallbladder and Bile Duct Disorders
Universitat de València
2013-2025
Hospital General Universitario De Valencia
2015-2024
Hospital Quirón Torrevieja
2010-2017
Hospital Clínico Universitario de Valencia
2014-2017
Cornell University
2016
Valencia Catholic University Saint Vincent Martyr
2015
Instituto de Salud Carlos III
2015
Clínica Girona
2011-2014
Hospital Marina Baixa
2013
Kyushu University
2013
Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment interferon in patients chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of plus ribavirin, alfa-2b initial C.
Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response therapy peginterferon alfa plus ribavirin.
Covalent attachment of a 40-kd branched-chain polyethylene glycol moiety to interferon alfa-2a results in compound (peginterferon alfa-2a) that has sustained absorption, slower rate clearance, and longer half-life than unmodified alfa-2a. We compared the clinical effects regimen peginterferon with those initial treatment patients chronic hepatitis C.
Available treatments for hepatitis B e antigen (HBeAg)-negative chronic are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues typically continued indefinitely, strategy the risk of resistance unknown long-term safety implications.We compared efficacy peginterferon alfa-2a (180 microg once weekly) plus placebo, lamivudine (100 mg daily), alone in 177, 179, 181 patients HBeAg-negative B, respectively. Patients were treated 48 weeks followed an...
In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic B, 24 week post-treatment biochemical and virological response rates peginterferon alpha-2a or without lamivudine were significantly higher than alone. The effect pre-treatment factors on responses was investigated.Multivariate analyses performed using available data from 518 treated lamivudine, A defined as alanine aminotransferase (ALT) normalisation virus (HBV) DNA level <20,000 copies/ml.In logistic regression...
Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial 19 Spanish hospitals, including 123 consecutive patients with genotype 1 C and insulin resistance. Patients were randomized receive either (arm A; n = 59) or placebo B; 64) addition peginterferon alfa-2a (180 microg/week) ribavirin...
Background & AimsPatients with nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated steatotic (MASLD) face multifaceted burden which includes impaired health-related quality of life (HRQL) and potential stigmatization. We aimed to assess the in patients NAFLD relationship between experience stigma HRQL.MethodsMembers Global NASH Council created a survey about NAFLD. Participants completed 35-item questionnaire Liver Disease Burden (LDB) (7 domains), 36-item CLDQ-NASH (6...
<b>Background:</b> Increased serum and intrahepatic interferon γ inducible protein 10 (IP-10) levels in patients with chronic hepatitis C (CHC) have been described. <b>Aim:</b> To analyse the possible association of IP-10 different outcomes to antiviral therapy. <b>Patients:</b> A total 137 CHC treated peginterferon plus ribavirin. <b>Methods:</b> Serum were determined by enzyme linked immunosorbent assay before therapy, after 12 weeks treatment, 24 cessation Variables significantly...